Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia
Authors:
- 1 April 1992
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 42 (4) , 353-358
Abstract
The effects of the HMG CoA reductase inhibitors lovastatin and pravastatin on serum lipids, lipoproteins and apolipoproteins have been studied in 35 patients with primary hypercholesterolaemia.Keywords
This publication has 36 references indexed in Scilit:
- Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanismsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991
- Efficacy and safety of pravastatin in patients with primary hypercholesterolemiaAtherosclerosis, 1990
- The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemiaJournal of Internal Medicine, 1990
- Long-Term Clinical Tolerance of Lovastatin and SimvastatinCardiology, 1990
- Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivoBiochemical and Biophysical Research Communications, 1989
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects A double blind testAtherosclerosis, 1988
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemiaThe American Journal of Cardiology, 1986